ANDA 210623, held by Ingenus Pharms LLC. Levoleucovorin Calcium.
As of Nov 16, 2026, ANDA 210623 (Levoleucovorin Calcium), held by Ingenus Pharms LLC, was first approved by FDA on May 3, 2018, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 3, 2018 | Original application | Approved | None posted |
| Levoleucovorin CalciumEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) · solution;intravenous | Levoleucovorin Calcium | Discontinued |
| Levoleucovorin CalciumEQ 250MG BASE/25ML (EQ 10MG BASE/ML) · solution;intravenous | Levoleucovorin Calcium | Discontinued |
| Sep 22, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 22, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 3, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters